9.89
-0.29 (-2.85%)
| Previous Close | 10.18 |
| Open | 10.04 |
| Volume | 330,013 |
| Avg. Volume (3M) | 5,124,861 |
| Market Cap | 775,804,608 |
| Price / Book | 3.16 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -3.07 |
| Total Debt/Equity (MRQ) | 18.32% |
| Current Ratio (MRQ) | 7.95 |
| Operating Cash Flow (TTM) | -192.25 M |
| Levered Free Cash Flow (TTM) | -110.31 M |
| Return on Assets (TTM) | -31.26% |
| Return on Equity (TTM) | -62.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Replimune Group, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -2.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.60 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.51% |
| % Held by Institutions | 107.50% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (Wedbush, 82.00%) | Buy |
| Median | 12.00 (21.34%) | |
| Low | 11.00 (BMO Capital, 11.22%) | Hold |
| 11.00 (JP Morgan, 11.22%) | Hold | |
| Average | 13.00 (31.45%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 9.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 03 Nov 2025 | 11.00 (11.22%) | Hold | 9.31 |
| HC Wainwright & Co. | 27 Oct 2025 | 12.00 (21.33%) | Buy | 9.33 |
| JP Morgan | 20 Oct 2025 | 11.00 (11.22%) | Hold | 8.95 |
| Leerink Partners | 20 Oct 2025 | 13.00 (31.45%) | Buy | 8.95 |
| Wedbush | 20 Oct 2025 | 18.00 (82.00%) | Buy | 8.95 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DHINGRA KAPIL | - | 10.30 | -3,169 | -32,641 |
| Aggregate Net Quantity | -3,169 | |||
| Aggregate Net Value ($) | -32,641 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 10.30 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DHINGRA KAPIL | Director | 09 Dec 2025 | Sell (-) | 3,169 | 10.30 | 32,641 |
| DHINGRA KAPIL | Director | 09 Dec 2025 | Option execute | 3,169 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |